Original ArticlesSymptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non–small-cell Lung Cancer
Key Words
Cited by (0)
Sarayut L. Geater and Chong-Rui Xu provided equal contribution.
S.L.G. has received honorarium from AstraZeneca. C.-R.X. has received payment for lectures including service on speaker bureaus from Eli Lilly and Roche. S.L. has received consulting fees from Boehringer Ingelheim, AstraZeneca, and Roche; payment for lectures including service on speakers bureaus from Lilly. M.P. has received money to his institution for grants and board membership from N Zero 1 Ltd. Y.S. and J.L. are full-time employees of Boehringer Ingelheim. Y.-L.W. has received consulting fees or honorarium from Roche, Eli Lilly, AstraZeneca, and Pfizer.
This study was funded by Boehringer Ingelheim. Medical writing assistance, supported financially by Boehringer Ingelheim, was provided by Katie McClendon, PhD, of GeoMed, an Ashfield company, part of UDG Healthcare plc, during the preparation of this article.
Presented, in part, at the 2014 European Society for Medical Oncology Meeting, September 26–30, 2014, Madrid, Spain; the 49th Annual Meeting of the American Society of Clinical Oncology, 31 May–4 June 2013, Chicago, IL; the 2013 European Respiratory Society International Congress, September 7–11, 2013, Barcelona, Spain; and the 16th Annual Meeting of the Chinese Society for Clinical Oncology, September 25–29, 2013, Xiamen, China.
This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives 3.0 License, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially.